Epidermal Growth Factor Receptor Mutations in the Blood of Patients With Advanced Non-Small Cell Lung Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2009 by National Cancer Institute (NCI).
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00899756
First received: May 9, 2009
Last updated: July 7, 2009
Last verified: July 2009

May 9, 2009
July 7, 2009
June 2006
Not Provided
  • Existence of epidermal growth factor receptor (EGFR) mutations in peripheral blood [ Designated as safety issue: No ]
  • Frequency of EGFR mutation [ Designated as safety issue: No ]
  • Correlation of the presence of EGFR mutation in blood with EFGR mutation in primary or metastatic tumor tissue [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00899756 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Epidermal Growth Factor Receptor Mutations in the Blood of Patients With Advanced Non-Small Cell Lung Cancer
Study of Mutations of Epidermal Growth Factor Receptor in the Blood of Patients With Advanced Non Small Cell Lung Cancer

RATIONALE: Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.

PURPOSE: This laboratory study is looking at epidermal growth factor receptor mutations in the blood of patients with advanced non-small cell lung cancer.

OBJECTIVES:

  • Determine if epidermal growth factor receptor (EGFR) mutation exists in the peripheral blood of patients with advanced non-small cell lung cancer (NSCLC).
  • Estimate the frequency of EGFR mutation in these patients.
  • Correlate the presence of EGFR mutation in blood with EGFR mutation in primary or metastatic NSCLC tumor block.

OUTLINE: Patients undergo blood collection for analysis of epidermal growth factor receptor mutation by DNA sequencing.

PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.

Observational
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
Lung Cancer
  • Genetic: molecular diagnostic method
  • Genetic: mutation analysis
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
50
Not Provided
Not Provided

DISEASE CHARACTERISTICS:

  • Histologically or cytologically confirmed advanced non-small cell lung cancer
  • Must have available tumor tissue block

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
Both
18 Years and older
No
Singapore
 
NCT00899756
CDR0000491609, JHOC-JS0538, JHOC-06-03-07-01
Not Provided
Not Provided
Sidney Kimmel Comprehensive Cancer Center
National Cancer Institute (NCI)
Study Chair: Alex Y. Chang, MD Johns Hopkins University
National Cancer Institute (NCI)
July 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP